Читать книгу Biologics, Biosimilars, and Biobetters - Группа авторов - Страница 74

Biologics markets are concentrated and crowded. Currently, the top 10 biologic therapies account for 36% of all biologic drug spending. The three largest biologic therapy areas (autoimmune, diabetes, and oncology) are worth US$110 billion, over half of all biologic drug revenue. They are represented in 9 of the top 10 biologics and are increasingly relevant due to their contribution to 70% of biologic market growth since 2010.¹⁴

Over half of the biologic pipeline is in therapy areas with few or no biologic treatments on the market. Their large presence in the pipeline is a sign of biologics broadening their therapeutic focus, bringing new therapeutic areas for growth.¹⁵